Trials / Completed
CompletedNCT03094845
Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients
Assessment of Safety and Clinical Tolerability of hdmASIT+TM Administered Subcutaneously in House Dust Mite-induced Allergic Rhinoconjunctivitis Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- ASIT Biotech S.A. · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
hdmASIT+TM product is based on highly purified allergen fragments from house dust mites. The purpose of this study is to assess the safety and clinical tolerability of subcutaneous immunotherapy with hdmASIT+TM in patients with house dust mite-induced allergic rhinoconjunctivitis compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Placebo solution | 15 injections over 7 weeks |
| BIOLOGICAL | hdmASIT+TM | 15 injections over 7 weeks |
Timeline
- Start date
- 2016-09-28
- Primary completion
- 2017-01-12
- Completion
- 2017-01-23
- First posted
- 2017-03-29
- Last updated
- 2017-03-29
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03094845. Inclusion in this directory is not an endorsement.